Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, Inc., filed a Form 4 on August 26, 2026, reporting the sale of 3,296 shares of common stock on August 24, 2026, pursuant to a Rule 10b5-1 automatic sale instruction to cover tax withholding obligations.
Key Highlights
- Shares sold: 3,296 shares of Ocular Therapeutix common stock were disposed of on August 24, 2026, with transaction code S.
- Weighted average price: Shares were sold at a weighted average price of $10.78, with individual transaction prices ranging from $10.6425 to $10.9125.
- Purpose of sale: According to the filing, the sale was made solely to satisfy tax withholding obligations connected to the vesting of restricted stock units on August 22, 2026.
- Automatic plan: The sale was executed pursuant to a durable automatic sale instruction adopted by Heier on April 9, 2024, and the filing states "the sales do not represent a discretionary trade by the reporting person."
- Beneficial ownership following transaction: Heier beneficially owned 318,326 shares of common stock directly after the reported transaction.
- ESPP shares included: The post-transaction total includes 1,272 shares of common stock acquired under the Corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026.
Ocular Therapeutix Chief Scientific Officer Reports RSU Vesting and Sell-to-Cover Transaction
Jeffrey S. Heier, serving as Chief Scientific Officer of Ocular Therapeutix, Inc. (NASDAQ:OCUL), reported a change in beneficial ownership following the vesting of restricted stock units. According to the filing, 3,296 shares were sold on August 24, 2026, under a durable automatic sale instruction that Heier adopted on April 9, 2024. The filing indicates this was a "sell-to-cover" election designed to satisfy tax withholding obligations arising from the RSU vesting on August 22, 2026.
The reported weighted average sale price was $10.78 per share, with individual transactions executed at prices ranging from $10.6425 to $10.9125, inclusive. The filing notes that Heier undertakes to provide full information regarding the number of shares sold at each separate price upon request by the corporation, any security holder, or SEC staff.
Following the reported sale, Heier directly held 318,326 shares of common stock. That total includes 1,272 shares acquired under the corporation's Amended and Restated 2014 Employee Stock Purchase Plan on June 30, 2026, as disclosed in the filing footnotes. The Form 4 was signed by Todd Anderman as Attorney-in-Fact for Jeffrey S. Heier and filed on August 26, 2026. No derivative securities transactions were reported.
What Was Disclosed
The filing reported a sell-to-cover sale of 3,296 common shares at a weighted average of $10.78 per share on August 24, 2026, tied to RSU vesting, executed under a pre-established Rule 10b5-1 automatic sale plan. Post-transaction direct ownership stood at 318,326 shares.



Please wait processing your request...